New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 10mg;   - tablet - 10 mg - active: methylphenidate hydrochloride 10mg   excipient: calcium phosphate gelatin lactose monohydrate magnesium stearate purified talc wheat starch - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 10mg;   - modified release capsule - 10 mg - active: methylphenidate hydrochloride 10mg   excipient: ammonio methacrylate copolymer gelatin macrogol 6000 methacrylic acid copolymer purified talc sugar spheres tekprint tan sw-8010 titanium dioxide triethyl citrate - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 20mg;   - modified release capsule - 20 mg - active: methylphenidate hydrochloride 20mg   excipient: ammonio methacrylate copolymer gelatin methacrylic acid copolymer type a-methacrylate acid-methacrylate copolymer 1:1, dry powder macrogol 6000 purified talc sugar spheres titanium dioxide triethyl citrate - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 30mg;   - modified release capsule - 30 mg - active: methylphenidate hydrochloride 30mg   excipient: ammonio methacrylate copolymer gelatin methacrylic acid copolymer type a/methacrylic acid methacrylate copolymer 1:1, dry powder iron oxide yellow macrogol 6000 purified talc sugar spheres titanium dioxide triethyl citrate - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 40mg;   - modified release capsule - 40 mg - active: methylphenidate hydrochloride 40mg   excipient: ammonio methacrylate copolymer gelatin methacrylic acid copolymer type a -/methacryllic acid-methacrylate coplymer 1:1 dry powder iron oxide black iron oxide red iron oxide yellow macrogol 6000 purified talc sugar spheres titanium dioxide triethyl citrate - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 20mg;  ;   - modified release tablet - 20 mg - active: methylphenidate hydrochloride 20mg     excipient: carbon dioxide carnauba wax cetostearyl alcohol hypromellose ink lactose monohydrate magnesium stearate methylated spirits polyethylene glycol hydrogenated castor oil purified talc purified water titanium dioxide - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 60mg;   - modified release capsule - 60 mg - active: methylphenidate hydrochloride 60mg   excipient: ammonio methacrylate copolymer gelatin iron oxide black iron oxide red iron oxide yellow macrogol 6000 methacrylic acid copolymer purified talc sugar spheres tekprint tan sw-8010 titanium dioxide triethyl citrate - ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - omalizumab 150mg - powder for injection with diluent - 150 mg - active: omalizumab 150mg excipient: histidine histidine hydrochloride polysorbate 20 sucrose water for injection - xolair is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have ige > 30 iu/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled iwth inhaled corticosteroids.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - omalizumab 75mg - injection with diluent - 75 mg - active: omalizumab 75mg excipient: histidine histidine hydrochloride polysorbate 20 sucrose water for injection - xolair is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have ige > 30 iu/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled iwth inhaled corticosteroids.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - omalizumab 150 mg/ml - solution for injection - 150 mg/ml - active: omalizumab 150 mg/ml excipient: arginine hydrochloride histidine histidine hydrochloride monohydrate polysorbate 20 water for injection - xolair (omalizumab) is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have ige greater than or equal to 30 iu/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.